clinical trial · NCT05757570
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
Alpine Immune Sciences, Inc.·phase2·active not recruiting·n = 30
Immune ThrombocytopeniaIdiopathic Thrombocytopenic PurpuraWarm Autoimmune Hemolytic AnemiaCold Agglutinin Diseasepovetacicept
brief summary
The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
started
Jul 3, 2023
primary completion
Jul 1, 2026
completion
Jul 1, 2026
last updated
Jul 4, 2025
official title
Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol